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Cardiovascular diseases (CVD) are the most common cause of mortality globally and can be 
defined as disorders of the heart and blood vessels. CVD mortality rate and complications are 
on the rise, especially in developing countries. Age, obesity, smoking, diet, hypertension, 
genetics and diabetes are a few of the risk factors associated with CVD. Atherosclerosis is a 
significant contributor to CVD and is characterised by an accumulation of atherosclerotic 
plaque in the arteries, over time causing narrowing of the vessel lumen, limiting flow and 
causing tissue ischemia as well as acute occlusion due to atherothrombosis. Atherosclerosis 
initiates via dysfunction or damage of the endothelial cells (EC) that line the vessel wall. 
Endothelial dysfunction is amplified at branch points and curved sections in the vessel wall, 
exposed to disturbed blood flow patterns and limited in regions of arteries exposed to laminar 
flow, leading to focal development of disease.  The protection in sections that experience 
laminar flow is predominantly driven through shear-regulated activation of KLF2, KLF4 and Nrf2 
and suppression of NFκB activation in endothelial cells. In turn regulating the expression of over 
1000 genes to modify endothelial behaviour and limit oxidative stress, inflammation and 
permeability. Huge amounts of research have been carried out to understand the processes, 
using a number of cell models to perform the research, including human coronary artery 
endothelial cells (HCAEC), which might be considered the gold standard, as well as human 
umbilical vein endothelial cells (HUVEC), because of their lower cost. This project assessed the 
relative gene expression of HCAECs and HUVECs cultured under identical conditions: static 
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culture, ‘plaque promoting’ oscillatory shear stress (±5 dynes/cm2, 1Hz), or ‘plaque-limiting’ 
physiological laminar shear stress (15 dynes/cm2).  We concurrently evaluated the response of 
endothelial colony forming cells (ECFC), under the same conditions, evaluating whether these 
blood isolated cells can also be used as a model to investigate pathological processes involved 
in atherosclerosis from different patient groups. Our data concluded that KLF2 is significantly 
upregulated by laminar flow in HCAECs, whilst KLF4 is significantly upregulated by flow in all 3 
cell types. The KLF2 and KLF4 responsive genes demonstrated a range of responses, with only 
eNOS showing significant upregulation in HCAECs by laminar flow. Additionally, Nrf2 regulated 
genes showed the largest upregulation in HCAECs under laminar flow whereas little difference 
was seen in within the NFκB regulated genes. The results obtained from the project provide 
evidence that HCAEC remain the most suitable cell model, with HUVECs demonstrating 
potential with additional work however ECFCs are rendered as unsuitable, due to their inability 
to provide significant upregulation of atherosclerosis-relevant genes.  
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1.1 Cardiovascular disease  
Cardiovascular disease (CVD) is the leading cause of fatality word-wide and is a continuing 
major problem within the healthcare industry, (Jackson, 2011). World Health Organisation 
(WHO) have recently updated cardiovascular disease statistics in a bid to highlight the 
growing impact and concern they have on the community and healthcare facilities. 
Rheumatic heart disease, cerebalvascular disease and coronary heart disease, amongst 
many more, fall under the cardiovascular disease category, with cardiovascular disease 
generically identified as ‘disorders of the heart and blood vessels’, (World Health 
Organization, 2019). In 2019, WHO have reported that CVD is estimated to account for 31% 
of deaths globally, (World Health Organization, 2019) (Brennan et al., 2017), with 85% of 
these CVD deaths a consequence of heart attacks or strokes, particularly prevalent in low 
and middle-income countries (World Health Organization, 2019). The human body’s 
vascular system’s primary function is to supply every tissue with adequate oxygen and 
nutrients (Hahn and Schwartz, 2009).  Impaired vascular function can lead to the onset of 
cardiovascular problems; such as atherosclerosis (Hahn and Schwartz, 2009).  




Atherosclerosis is a major cause of CVD and is initially asymptomatic, developing over 
decades. Atherosclerotic plaque formation within arteries can limit blood flow leading to 
tissue ischemia, for example, angina if in the heart or peripheral vascular disease, causing 
limb ischemia. Disruption of atherosclerotic plaques, by plaque rupture, plaque erosion or 
eruption of a calcified nodule, can trigger thrombosis and lead to acute occlusion, giving 
rise to acute ischemia, tissue damage, loss of organ function and death (White et al., 2016). 
If in the heart, it may trigger myocardial infarction, if affecting the blood supply to the brain, 
it can cause a stroke.  
Atherosclerosis is a lipoprotein-driven, chronic inflammatory disease of the arterial wall 
involving progressive lesion formation and frequently causes narrowing of the arterial 
lumen (Weber and Noels, 2011). Atherosclerosis initiates at sites of disturbed flow, where 
reduced nitric oxide bioavailability allows smooth muscle cells to migrate and proliferate 
and form an intimal hyperplasia containing both smooth muscle cells and extracellular 
matrix (Hahn and Schwartz, 2009). Concurrent with this, the barrier function of the 
endothelium is also reduced, allowing more low-density lipoprotein to pass into the arterial 
wall. This becomes trapped within the neointima, where it oxidises over time, triggering 
the increase in expression of inflammatory cytokines (e.g. CCL2) and expression of adhesion 
molecules on the endothelium (Hahn and Schwartz, 2009). Uptake of ox-LDL by recruited 
monocyte-derived macrophage as well as smooth muscle cells, contributes to foam cell 
formation, further driving cytokine expression, inflammatory cell recruitment, endothelial 
dysfunction and plaque expansion (Spartalis et al., 2019).  
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Figure 1: Atherosclerotic plaque. An example of atherosclerosis, plaque formation within an artery 
wall in vivo. This diagram demonstrates elevated sheer stress upstream to the blood flow and 
disturbed sheer stress on the downstream surface, both of which are crucial in the modification of 
endothelial cell behaviour. (White, Newby and Johnson., 2016). 
 
Atherosclerosis develops focally at predicable sites within the arterial system, as 
demonstrated by figure 1.  Bifurcation sites and regions of high curvature in arteries 
exposed to disturbed shear stress are predisposed to the onset of atherosclerosis (Dai et 
al., 2004). Regions exposed to low time-averaged wall shear stress and high oscillatory 
shear index/multidirectional flow strongly correlated to plaque formation (Hoogendoorn 
et al., 2019). The association between the focal nature and atherosclerosis and flow pattern 
demonstrates the key role that vascular endothelium plays in regulating the processes that 
drive atherosclerosis. 
 
1.3 Vascular Endothelium  
Defined as a monolayer of endothelial cells that line all blood vessels and lymphatics 
(Dimitris Tousoulis, 2019), the vascular endothelium is responsible for the regulation of 
vascular tone, thrombolysis and transport of molecules to the sub-endothelial space. This 
in turn regulates smooth muscle cell function, controlling proliferation and migration 
(Boulanger, 2016).  Endothelial cells are mechanosensitive and are able to respond and 
react to different blood flow patterns, sensing the frictional force exerted upon their 
surface (shear stress) and cyclical stretch, converting these mechanical stimuli into a 
biological response (Baratchi et al., 2017, Charbonier et al., 2019). 
 
1.4 Endothelial Cells and Mechano-sensing 
Proteins belonging to the EC glycocalyx play a major role in transmitting shear stress to 
mechanoreceptors, which include integrins, ion channels and junctional receptors 
(Baratchi et al., 2017). Through syndecans connected to the cytoskeleton, or through 
glypicans connected to the plasma membrane, the glycocalyx can also transduce other 
shear sensors embedded in the plasma membrane, or focal adhesions and intracellular 
junction proteins via the cytoskeleton (Givens and Tzima, 2016).  
 
The release and synthesis of pro and anti- anticoagulant factors, alongside growth factors, 
vasomotor regulators, Von Willebrand Factor and TNF-a, is dependent upon 
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mechanotransmission through EC ion channels. Ion channels play a key role when it comes 
to the sensing of shear stress in the vascular endothelium and when shear stress-
dependant Ca2+  channels are stimulated, a rapid influx of Ca2+   is released into the EC 
cytoplasm, resulting in activation of endothelial nitric oxide synthase (eNOS) and NO 
(Baratchi et al., 2017) . In addition, transmission of force exerted by shear stress on the cell 
surface, to a tri-protein complex in intercellular adherent junctions, activates a 
phosphorylation signalling cascade downstream of platelet endothelial cell adhesion 
molecule-1 (PECAM1) (Baeyens and Schwartz, 2016). The cascade includes 
phosphorylation and activation of integrins that bind extracellular matrix (ECM) 
components and in turn  activates Src-dependent signalling which eventually activate 
transcription factors KLF2 and KLF4, via ERK5 modulating the expression of over 1000 genes 
in endothelial cells to mediate the laminar flow-induced quiescent atheroprotective 
phenotype (Dekker et al., 2006).  
 
Mechanotransduction in EC through the endothelium is further regulated by focal 
adhesions, lying on the basal plasma membrane these protein complexes also drive integrin 
adhesion to the extra cellular matrix (ECM). Both EC and vascular smooth muscle cells are 
subjected to cyclic stretch by the pulsatile nature of blood flow. The literature is slightly 
misleading, with short-term exposure triggering an adaptive response, often interpreted as 
inflammatory (Ramella et al., 2019). EC exposed to ‘short-term’ cyclic stretch pathologically 
change their function, structure and morphology (Ramella et al., 2019). In contrast, in vivo, 
the cyclic strain is orientated 90° to shear stress, with laminar flow experienced along the 
long axis of the cell, with 3-5% cyclic strain across the cell’s short axis. This enhances the 
quiescent, atheroprotective phenotype of endothelial cells (Lu and Kassab, 2011). 
 
1.5 Nitric oxide 
Under normal functional conditions in vivo, the endothelium is able to regulate the 
production of soluble gas vasodilator; nitric oxide (NO), which is continuously synthesized 
from L-arginine by calcium co-comodulant enzyme; endothelial nitric oxide synthase 
(eNOS) (Weber and Noels, 2011). The activity of eNOS is regulated by shear stress, 
particularly through Ca2+ signalling, but also through phosphorylation cascades, to 
modulate vessel tone of the large arteries, dependent on the blood supply needs of the 
distal tissue. The physiological functions of NO are crucial, acting directly on local ECs and 
underlying smooth muscle cells, participating in nitrosylation reactions to regulate local cell 
11 | Page 
 
growth and play a protective role as a consequence of vessel wall injury (Weber and Noels, 
2011). Alongside supressing major inflammation regulator NFκB, NO also regulates platelet 
function and contributes to anti-thrombotic function of the endothelium. Platelet and 
endothelium-released NO inhibits platelet adhesion to the vessel wall by promoting the 





















Figure 2: Formation of a thrombus. Healthy/ uninjured endothelium produces sufficient NO to prevent 
activation and adhesion of platelets, therefore preventing thrombus formation. When endothelium 
becomes damaged, platelet adhesion is increased, releasing prothrombotic substrates which promote the 






1.6 Endothelial dysfunction 
Disturbed flow doesn’t activate the athero-protective signalling and gene expression 
pattern that is induced by laminar flow, priming the endothelium for inflammation and 
dysfunction (Warboys et al., 2011). The lack of the laminar flow-induced phenotype in 
endothelial cells increases the relative production of reactive oxygen species (ROS), priming 
the activation of NFκB. eNOS activity is reduced at sites of disturbed flow, coupled with 
quenching the NO produced by ROS, leading to a very much reduced bioavailability of NO 
(Warboys et al., 2011). The enhanced activation of NFκB increases the expression of 
adhesion molecules (particularly VCAM1 and ICAM1) and the production of cytokines (e.g. 
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CCL2) stimulating monocyte adhesion. On a molecular scale, endothelial dysfunction is 
therefore defined as an increase in ROS production, reduced bioavailability of NO and the 
increase in adhesion molecule and cytokine expression (Charbonier et al., 2019).  In a 
pathological state, ROS can negatively interact with endothelial cell ion channels and 
transcription factors, establishing alterations in lipid metabolism and heightening cell 
permeability potential, apoptosis, growth factor modifications, contributing to 
endothelium dysfunction (Carnevale et al., 2018). Endothelial dysfunction is recognized as 
a major contributor in the initiation of atherosclerosis and is highly associated with changes 
which create a diminished output in the production of the bioavailability of nitric oxide and 
an increase in oxygen free radical formation (Satta et al., 2017). Oxidation of lipoproteins 
and foam cell formation relate back to facilitation of vascular inflammation and are 
demonstrated to be a consequence of a reduced output of nitric oxide bioavailability also 
(Silva et al., 2012).  
 
 
1.7 Oxidative Stress and Reactive Oxygen Species 
Growing evidence supports the important and significant role that oxidative stress plays in 
atherosclerosis, alongside its important influence in disturbed blood flow pattern 
phenotype of endothelial cells (Charbonier et al., 2019).  Oxidative stress can be defined as 
the imbalance in production of reactive oxygen species (ROS) and the anti-oxidant defence 
system, which favours the increase of the toxic product of oxygen metabolism, ROS  
(Howden, 2013, Satta et al., 2017) A large number of cardiovascular risk factors contribute 
to, or mediate their effect on the disease process through increasing endothelial 
dysfunction. Diabetes, obesity, smoking, and dyslipidaemias are not only all pro-
atherogenic and risk factors for CVD, they also increase permeability dysfunction in 
endothelial cells through an imbalance in ROS production (Mundi et al., 2017). ROS are 
produced naturally within endothelial cells and smooth muscle cells, occurring within the 
vasculature, and their components include both free radical and non-radicals and 
participate in cell growth, death, inflammatory response and regulation of vascular tone 
(Carnevale et al., 2018). ROS are generated within the vessel wall from a variety of 
mechanisms including NADPH oxidase (Kattoor et al., 2017). NAPDH has shown crucial 
involvement to being a major source of ROS and elsewhere, extensive research has been 
recorded, showing a strong correlation between NAPDH and adhesion molecule 
expression, monocyte infiltration, SMC proliferation and superoxide anion generation 
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(Kattoor et al., 2017). Depletion of eNOS substrate, L-arginine, or cofactor 
tetrahydrobiopterin (BH4), may trigger eNOS uncoupling and ROS production further 
decreasing the bioavailability of NO and an increasing in O2 generation. An elevated 
production of ROS, or a failure to quench it, results in oxidative stress that damages DNA, 




A reduction in the bioavailability of NO, coupled with ROS generation and an increase in 
growth factor exposure due to increased endothelial permeability, promotes proliferation 
and migration of smooth muscle cells (SMCs) (Kattoor et al., 2017; Chen et al., 2016). In 
healthy blood vessels SMCs remain in a quiescent state with a very low rate of proliferation. 
SMCs play a key role in the regulation of blood flow, blood pressure and maintenance of 
vascular tone. Their quiescent state is maintained through the expression of the proteins 
such as smooth muscle actin, smooth muscle-calponin and smooth muscle 22-alpha, (Chen 
et al., 2016). Reduced exposure to NO and increased growth factor exposure allows a few 
SMCs to undergo ‘phenotypic switching’ (Basatemur et al., 2019; Bennett, Sinha and 
Owens, 2016) This phenotypic switch is associated with an upregulation in secretion of pro-
inflammatory mediators, tissue factor (TF), matrix metalloproteinase (MMP’s) and 
inflammatory cytokines, resulting in migration to the intima, proliferation and production 
of extracellular matrix (ECM) (Jeremy et al., 1999).  
Under normal circumstances, the endothelial barrier has highly selective permeability, 
minimising ingress of blood-borne factors, importantly low-density lipoproteins (LDLs). The 
amplification of endothelial dysfunction at sites of disturbed flow, reduces barrier function, 
increasing permeability as well as promoting an ‘activated’ EC state (Mudau et al., 2012). 
Increased rates of LDL entry at sites of disturbed flow increases the trapping of LDL within 
the intimal hyperplasia generated by SMC migration and proliferation. Trapped LDL 
becomes modified by oxidation and glycation reactions, promoting inflammatory 
signalling. Activated EC cells increase expression of monocyte adhesion molecules (VCAM1 
and ICAM1 ) and chemoattractant cytokines e.g. TNFα, CCL2 and CX2CL3 promoting 
immune cell rolling, tethering and firm adhesion, enabling trans-endothelial migration of 
monocytes to the sub-endothelium. Here, recruited monocytes transform into 
macrophages via cytokine stimulation where they take up oxLDL via scavenger receptors, 
transforming into foam cells if the amount is high. Continued high levels of ingress of LDL 
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at sites of disturbed flow creates a state of localized inflammation within the intima, 
encouraging further recruitment of immune cells in turn increasing producing of 
inflammatory cytokines, accelerating the formation of an atherosclerotic plaque (Baker et 
al., 2011). 
 
1.9 Athero-protective phenotype of ECs 
Unidirectional Laminar shear stress exerts its atheroprotective effect on the endothelium 
predominantly through the upregulation of Krupple-Like Factors KLF2/KLF4, activation of 
Nrf2 (encoded by gene NFE2L2) (Howden, 2013; Satta et al., 2017) and a suppression of 
pro-inflammatory signalling via NFκB (Hahn and Schwartz, 2009; Satta et al., 2017; Warboys 
et al., 2011).  
 
1.9.1 Krupple Like Factor 2/4 
 
Krupple-like factors (KLF), a family of transcription factors, accumulate mainly in the cell 
nucleus and can act as either transcriptional activators or repressors, which function 
physiologically by either DNA-binding or interacting with their co-factors to express their 
effects (Jain et al., 2014). KLF2 and KLF4 collectively regulate over 1000 genes that control 
anti-inflammatory and anti-thrombotic properties of ECs, modulating barrier function of 
the vascular endothelium and EC quiescence (Theodorou and Boon, 2018). Upon induction 
of the KLFs through high shear stress, KLF2 and KLF4 translocate to the nucleus. One of 
their major co-factors for transcriptional activation is p300, which is also a co-factor for 
NFκB. (Jain et al., 2014). Competition for p300 between KLF2/4 and NFκB is one of the ways 
which laminar flow reduces NFκB-mediated gene expression, with the elevated expression 
in laminar flow favouring the upregulation of KLF2/4 responsive genes (Jain et al., 2014).   
 
 
The group of protein kinases collectively known as MAP Kinases, induce cellular 
mechanisms such as apoptosis, proliferation and inflammation.  Pathways activated by 
inflammatory cytokines include the JNK and p38 pathways to activate transcription factor 
AP1 and activating transcription factor 2 (ATF2) (Warboys et al., 2011).  The MAPK and NFκB 
pathway are both clearly indicated in endothelial activation at regions of disturbed flow 
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however laminar shear-induced KLF2 reduces MAPK’s proinflammatory gene expression 
through inhibition of the nuclear localization of ATF2 (Fledderus et al., 2007).  
 
KLF2 and KLF4 upregulation by shear stress is predominantly mediated via a different MAP 
kinase extracellular signal-related kinase 5 (ERK5), promoting the induction of the athero-
protective phenotype in arterial ECs (Dekker et al., 2006; Parmar et al., 2006). Laminar 
shear stress induces the phosphorylation of ERK5, which in turn increases the expression 
of both KLF2 and KLF4, thereby coordinating the upregulation of over 1000 genes, with 
examples in table 1 (Dekker et al., 2006;  Parmar et al., 2006). ERK5 possess a long COOH 
terminal, which is responsible for the activation of downstream transcription factors 
involved in anti-inflammatory processes, through transcriptional activity domains (Bera et 
al., 2014). Therefore, ERK5 activation is associated with increased quiescence, reduced 
apoptosis and migration, alongside reduction in the expression of adhesion molecules, 
VCAM1 and ICAM1 (Ramella et al., 2019).  Studies using animal models have shown that 
ERK5-deificent mice have a short life span and die due to cardiovascular defects and 
angiogenic failure (Nithianandarajah-Jones et al., 2014).  
 
Table 1: Target genes of KLFs 
Target Genes of KLF2/4 Gene 
Abbreviation 
Function 
Thrombomodulin THMB Anti-thrombotic/ Anti-inflammatory 
Nephroblastoma Overexpressed NOV  
Peptidase Inhibitor 16 PI16  
Endothelial Nitric Oxide Synthase eNOS Regulates NO production/ Anti-
inflammatory 
Nitric Oxide NO Anti-inflammatory/ Vasodilator 
Von Willebrand Factor  VWF Haemostasis 
Adrenomedullin ADM Vascular tone regulation  
Nad(P)H Quinone Dehydrogenase 1 NQO1 Vascular tone regulation 
Protein C Protein C Anti-thrombotic 
   
 
In arterial endothelial cells, examples of genes responsive to KLF2/4 include; eNOS, THMB, 
peptidase inhibitor 16 (PI16) and neuroblastoma overexpressed (NOV). As previously 
mentioned, eNOS regulates the production of NO under laminar shear stress, promoting 
an anti-inflammatory and atheroprotective effect on the cell (Weber and Noels, 2011).  
 
Expressed in all tissues and synthesized predominantly in endothelial cells, 
thrombomodulin is an integral transmembrane protein whose transcription is regulated by 
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shear stress through involvement of transcription factor; KLF2 (Yau et al., 2015).  Healthy 
vascular endothelium expresses various anti-coagulant properties, including THMB, which 
serves a purpose of down-regulating platelet mechanisms and thrombotic events, 
essentially preventing the formation of a thrombus (Martin et al., 2014). Extensive research 
has been conducted into the activation of thrombomodulin through laminar shear stress 
and it has been demonstrated to drive three anti-coagulant activities, including: catalysing 
thrombin-induced activation of protein C to activated protein C, binding with thrombin to 
prevent conversion of fibrinogen to fibrin and activation of platelets, fV, fVIII, fXI, and fXIII, 
and catalysing the inhibition of thrombin by anti-thrombin (Yau et al., 2015). Through the 
expression of thrombomodulin, endothelial cells can regulate protein c activation, 
conjunctively responsible for regulating thrombosis and decreasing inflammatory 
responses, reducing downstream effects of cell apoptosis in response to damage and injury 
(Yau et al., 2015). Thrombomodulin also holds direct anti-inflammatory activity where it 
reduces cytokine formation in the endothelium simultaneously decreasing leukocyte-
endothelial cell adhesion (Esmon, 2003). 
 
1.6.2 Nuclear Erythoid-2 Like Factor 
 
First identified as a component involved in the regulation of oxidant and antioxidant gene 
expression by Moi et al in 1994, Nrf2 is now recognized as a major regulator of the 
antioxidant/oxidant balance and directs cellular responses to oxidative and free radical 
stress (Satta et al., 2017). Nrf2 coordinates the expression of many of the enzymes involved 
in the antioxidant defence that  counteracts and protects the cell from damage(Howden, 
2013; Satta et al., 2017). Sustained high-level activation of Nrf2 may however be 
detrimental. The White lab have shown that overexpression of Nrf2, or regulated genes 
OSGIN1+2 cause cell detachment and may be a trigger of endothelial erosion and resultant 
thrombosis and infarction (Satta et al., 2019). 
 




















Figure 3: NRF2/KEAP1 Signalling Pathway. Diagram of the Nrf2 and Kelch-like-ECH associated 
protein pathway. We can see demonstrated here that under normal conditions KEAP1 is 
suppressing the activation of Nrf2, KEAP1 is therefore responsible for constant ubiquination of 
Nrf2 within the proteasome of the cell. Alternatively, oxidative stress (ROS) causes inactivation of 
KEAP1 resulting in phosphorylation of Nrf2 and accumulation in the nucleus. Here, Nrf2 
heterodimerises with small MAFS (SMAFS) where it binds to antioxidant response element (ARE) 
activating appropriate genes (Oh and Jun, 2017).  
 
 
Laminar shear stress activates Nrf2 through two complementary mechanisms, firstly 
through lipid peroxides (Warabi et al., 2007) and secondly via a COX-2 mediated pathway 
(Hosoya et al., 2005). Without activation, Nrf2 is bound to its inhibitor KEAP1, which 
mediates its ubiquitination and degradation by Cu13 (Mimura and Itoh, 2015; Warabi et 
al., 2007). The interaction between KEAP1 and Nrf2 can be electrophilically attacked, 
liberating Nrf2allowing translocation to the nucleus (Satta et al., 2017) Lipid peroxidation 
is strongly correlated to Nrf2 activation, however it is unclear how shear stress leads to lipid 
peroxidation signalling (Warabi et al., 2007). Once in the nucleus, Nrf2 heterodimerizes 
with small MAFs (sMAFs), and binds antioxidant regulatory element (ARE) (consensus 
binding sequence (A/G)TGACTCAGCA), this complex upregulates enzymes and proteins 
which have crucial functions in protecting the cell from toxicity and oxidative stress (Warabi 
et al., 2007) (Satta et al., 2017; Mimura and Itoh, 2015). 
 
In addition, laminar flow-induced KLF2 expression also enhances upregulation of 
antioxidant and detoxifying responses, through priming Nrf2 activation. KLF2 increases the 
nuclear translocation and accumulation of Nrf2, through an undefined mechanism, 
18 | Page 
 
synergising with the other mechanisms by which shear stress activates Nrf2 to provide the 
atheroprotective effect of laminar flow (Fledderus et al., 2008; Satta et al., 2017). Not only 
does KLF2 prime Nrf2 for activation, it is also crucial for optimal activation of shear stress-
mediated Nrf2 binding to the ARE (Boon et al., 2008). In HCAECs, Nrf2 regulate the 











Table 2: Target genes of Nrf2. 
 
 
HMOX1 is thought to contribute to prevention of EC damage through the degradation of 
heme, the generation of anti-oxidants and the production of a vasodilator carbon 
monoxide (CO) (Kishimoto et al., 2019). Bilirubin is a by-product of HMOX1 with a lipophilic 
property protecting EC membranes from cell damage as well as protecting LDL from 
oxidisation (Kishimoto et al., 2019). In response to ROS production, Nrf2 activation in 
endothelial cells show an increase in heme-oxygenase 1 (HMOX1), nicotinamide adenine 
Target Genes of Nrf2  Gene Abbreviations  Function 
Heme Oxygenase 1  HMOX1 Antioxidant generator/ degrades Heme 
Oxidative Stress Induced 
Growth Inhibitor 1 
 OSGIN1 Antioxidant generator  




 NQO1 Protection from oxidative stress 
Matrix 
Metalloproteinase  
 MMP1/3 Degradation of extracellular matrix/ 
proteins 
Hephaestin   HEPH Metabolism/ Homeostasis of iron  
Glutamate Cysteine 
Ligase  
 GCLM Glutathione pathway/ Antioxidant 
Glutamate Cysteine 
Ligase 
 GCLC GCLM Catalytic Sub Unit 
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dinucleotide phosphate quinone 1 (NQO1), oxidative stress induced growth inhibitor 1 
(OSGIN1), glutathione (GSH) and glutamate cysteine ligase (GCLM), CO produced from 
HMOX1 has shown reduction effects against intracellular ROS production through the 
inhibition of NAPDH oxidase (Kishimoto et al., 2019). Over oxidation causes inhibition of 
important peroxiredoxins, which are crucial to the reduction of ROS, such as hydrogen 
peroxide, through Nrf2 these peroxiredoxins can be re-activated by regulating the gene 
expression of SRXN1 (Kunnas et al., 2016). Nrf2 mediated OSGIN1 protects the cell from 
oxidative and inflammatory stress through MMF-pathways – induced by the KEAP1-
cystienes interaction (Brennan et al., 2017). 
 
1.6. 3 Suppression of Nuclear Factor KB 
 
In the pathophysiology of atherosclerosis, NFκB is regarded as a key inflammatory regulator 
controlling proatherogenic processes including inflammation, cell proliferation and cell 
apoptosis, cytokines, cell adhesion molecules and chemokines (Baker et al., 2011). 
 
NFκB activation is tightly regulated at several levels, from receptor activation, potentiation 
of the phosphorylation cascade and feedback through upregulation of inhibitor of KBα 
(IκBα) (Figure 4) (de Winther et al., 2005).  IκBα has a binding site for NFκB in its promoter 
and is upregulated by NFκB signalling, providing a negative feedback loop that limits NFκB 
activation. Binding of IκBα to NFκB masks the nuclear localization signal, preventing 
translocation to the nucleus and activation of gene expression (Warboys et al., 2011). Upon 
activation of receptor signalling, phosphorylation of IKK phosphorylating IκBα, causing 
IκBα’s dissociation from NFκB and resulting in its ubiquination and degradation (Warboys 
et al., 2011;  Kanters et al., 2003). DNA binding and transcription is also facilitated through 
phosphorylation of NFκB (Warboys et al., 2011).  
 
 














Figure 4: MAPK and NFκB pathways. Activation of inflammation drivers; VCAM1 and ICAM1, 
through the MAPK and NFκB pathways. IκBα is dissociated from NFκB through phosphorylation of 
IKK, IκBα is then subsequently degraded and transcription of inflammatory genes is regulated 
through NFκB s migration to the nucleus. the MAPK pathway demonstrates the MKK, JNK and p38 









Table 3: Target genes of NFκB. 
 
 
MAPK and NFκB are both pathways which are equally implicated in inflammation and lesion 
development, since their regulation is notably differential between sites which are 
atheroprone and atheroprotective (Warboys et al., 2011). For example, the expression of 
cell adhesion molecules ICAM1 and VCAM1 are regulated both by NFκB, but also MAPK via 
phosphorylated ATF2 binding to their promoters, indicating the synergy between these 
pathways. KLF2 reduces JNK activity, via inhibition of protein kinase C elipson, (Warboys et 
Target Genes of NFκB Gene Function 
Cytokines/Chemokines TNF-a, IL-1, IL-2, IL-6, IL-8, IL-12 Inflammatory response and 
angiogenesis  
Cell Adhesion Molecules ICAM-1, VCAM-1, MMP’s Adhesion and invasion 
Cyclins and Growth Factors G-CSF, M-CSF, Cyclin D1 Cell Proliferation 
Regulators of Apoptosis IAPs, Bcl-XL Cell Apoptosis and 
Regulation 
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al., 2011).  As previously stated, KLF2/4 compete with NFκB for their shared activating co 
factor p300 (Jain et al., 2014). Therefore, laminar shear stress-induced upregulation of KLF2 
suppresses both NFκB and MAPK-driven inflammation by multiple pathways. 
 
Endothelial research 
Multiple cell types have been used to study the response of the endothelium to laminar 
and disturbed flow, including Human coronary artery endothelial cells (HCAEC), human 
aortic endothelial cells (HAoEC), Human umbilical vein endothelial cells (HUVEC) and 
bovine aortic endothelial cells (BAoEC). Additionally, the use of late outgrowth endothelial 
colony forming cells (ECFCs) and endothelial cells derived from induced pluripotent stem 
cells (IPS-ECs) offer the possibility of generating endothelial, or endothelial-like cells from 
the blood or tissue biopsies of patients, allowing influence of patient characteristics on 
endothelial behaviour to be more easily modelled. The potential relevance of each of these 
different endothelial cells to study the cell processes involved in initiating or driving 
atherosclerosis to be has not been investigated. A side-by-side comparison of each cell type 
to determine the suitability of each cell type as cell models, would allow the most suitable 




The aim of this research project is to perform comparative tests on several different 
endothelial cell lines to identify the best and most cost-effective cell model to perform 
research into the endothelial-dependent processes that regulate atherosclerosis. For this 
study we have selected to compare HCAECs, HUVECs and ECFCs. HCAECs are considered 
the most relevant cell line for the study of atherosclerosis, because of their relevance to 
cardiovascular disease and acute coronary syndromes. However, HCAECs are expensive to 
buy originate from a single donor and are supplied at passage 2, limiting the number of 
passages possible, before they undergo replicative senescence. For this reason, many 
studies choose to use HUVECs, which are comparatively cheap (approx. £100 rather than 
£500 per batch). They are often purchased as pooled donors, reducing the effect of each 
donor’s genetics and epigenetics on the responses being measured. ECFCs offer the ability 
to investigate endothelial function from patients with particular risk factors e.g. diabetes, 
hypertension, defined genetic mutations, allowing the effects of these traits on endothelial 
function to be investigated.  
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Analysis of gene expression of each of these cell types in identical media under identical 
culture conditions will identify whether there are significant differences between HCAECs 
and HUVECS or ECFCs and determine if they are all suitable models for atherosclerosis 
research. 
 
2.0 Materials and methods 
 
Cell culture 
Ethical approval for project granted from Manchester met university through Ethos review. 
Separate ethical approval for collecting blood and generating ECFCs had already been 
established.  
Endothelial Colony Forming Cells 
Deriving ECFC 
ECFC were derived fresh from the buffy coat of 3 different healthy donor’s blood by a fully 
trained phlebotomist. All blood work was performed under the same sterile conditions as 
the other cells, along with the same materials.   
The phlebotomist took approximately 60-70mls of blood from each donor and 4-6 falcon 
tubes were used (dependant on the volume of blood), were 20mls of Ficoll-Pique was 
added. The blood: PBS solution was then carefully layered on top. Prior to centrifugation 
of the blood solution a ‘cloudy’ layer can be seen, ECFC reside within this layer and 
approximately 12mls of this cloudy layer was added to a separate tube with an additional 
3mls of PBS. The new ECFC/PBS solution was centrifuged again where a pellet was left 
behind, after removal of supernatant. Although the pellet is not always visible, it was 
further suspended in 9mls of endothelial cell media.  
Culturing ECFC 
900ul of collagen and 8.1mls of PBS were combined in a falcon tube and vortexed. Two 
sterile plastic 6-well plates were coated with 1ml of the solution along with 1ml of the pellet 
solution. The ECFC are able to bind to the collagen coating and another 2ml of endothelial 
cell media is added to each well, with 4ml in total in each well. Media was changed the day 
after the cells had been plated, using the same media, and every other day following from 
that.  




Human Coronary Artery Endothelial Cells (HCAECs) and Human Umbilical Vein Endothelial 
Cells (HUVECs) were purchased from PromoCell whilst Endothelial Colony Forming Cells 
(ECFCs) were derived from healthy blood donors, all cell types were used at a passage 
between 2-6. All cell types were cultured under identical conditions and grown in the same 
media for at least one passage, MV2 Endothelial Cell media supplemented with a 5ml 
aliquot of penicillin: streptomycin (PromoCell). All analysis was performed on ECs seeded 
onto gelatin coated glass slides to standardise the experiments. The aim was to perform all 
experiments on confluent monolayers of ECs. To achieve this, 2.5x105 HCAECs or ECFCs, or 
3.5x105 HUVECs (due to their naturally smaller size) were seeded onto a gelatin coated 
slide, within a silicon gasket, which has a growth area of approximately 9.3cm2. ECs were 
cultured for 72 hours on the slides to allow complete confluency to be achieved. ECs were 
then cultured under static conditions, or flowed conditions using our established parallel 
plate flow apparatus to expose the ECs to ‘athero-prone’ oscillatory flow (OSS = ±5 
dynes/cm2, 1 Hz) or ‘athero-protective’ laminar flow (LSS = 15 dynes/cm2). ECs were 












Figure 5: Parallel flow plate. Demonstrating the structure of the parallel flow plate where cells were 
placed under mimicked atheroprone and atheroprotective flow conditions. 
 
Table 4: MV2 Endothelial Cell Media 
Reagent Quantity 
Endothelial Cell Medium MV2  500 ml 
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Fetal Calf Serum 0.5 ml 
Epidermal Growth Factor 5 ng 
Basic Fibroblast Growth Factor 10 ng 
Insulin Like Growth Factor 20 ng 
Vascular Endothelial Growth 
Factor  
0.5 ng 
Ascorbic Acid 1 ul 
Hydrocortisone  0.2 ug 
 
Table 5: DMEM Complete 
 
Reagent Volume 
DMEM 435 ML 
FBS 50 ML 
L-Glutamine 10ML 
Penstrep 0.5 ML (1x) 
 
Table 6: Reagents used for cell culture 
Reagent Brand Name  Catalogue Number 
DMEM Sigma D6546 
MV2 Endothelial Cell Media PromoCell C22221 
Trypsin Lonza BE17-161E 
Attachment Factor Gibco - 




PBS Lonza 17-516F 
 
 
Cell Lysis and Obtaining Samples 
Following exposure to identical culture conditions, the individual slides were washed in 
cold PBS on ice, and phase contrast images obtained at a magnification of X5 and X20, to 
allow comparison of morphology. Cells were then lysed in 300µl SDS lysis buffer [2% SDS; 
50 mM Tris pH 6.8; 10% glycerol] and 150µl immediately transferred to RNA lysis buffer 
(Norgen) allowing both protein and RNA analysis form the same sample. Samples were 
stored at -80°C, until further use. 
Table 7: Reagents used for cell lysis 
Reagent  Brand Name Catalogue Number 
Double Distilled Water -  -  
Glycerol -  -  
Tris Base Fisher Scientific BP152-1 
SDS   
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RNA Isolation and PCR 
Total RNA extraction was achieved using the Norgen Biotek Total RNA Purification kit 
according to the manufacturer’s instructions. Briefly, lysates were passed through a DNA 
binding column to reduce the amount of contaminating genomic DNA in the purified RNA 
sample. Following this, lysates were then passed through an RNA binding column before 
being washed 3 times. The RNA was then eluted, quantified using a nanodrop and stored 
at -80°C for further analysis. One advantage of using the Norgen kit is that it purifies both 
long and short RNAs to facilitate both mRNA + lncRNA and also miRNA analysis.   
Table 8: Reagents and materials used for RNA isolation 
Reagent Brand Name Catalogue Number 
Ethanol  -  -  
Beta-Mercaptoethanol  Sigma  8.05740 
Total RNA Purification kit Norgen Biotek 48300 
 Reverse Transcription Kit Qiagen 205311 
 
Reverse Transcription 
In preparation for Quantitative Polymerase-Chain Reaction (qPCR), cDNA was produced 
using the Qiagen Reverse Transcription Kit. RNA samples were thawed on ice along with 
the RT kit reagents. Whilst samples thawed, the following RT Master Mix were pre-
prepared:  
• 0.9ul of RT Enzyme per RNA sample 
• 4ul of RT Mix per RNA sample 
This master mix was then briefly mixed and stored on ice until further use. 1µl of genomic 
DNA (GDNA) Removal reagent was added to each individual sample, along with RNase-and 
DNase-free H2O to a total volume of 15µl. Samples were incubated at a temperature of 
45°C for 2 minutes, before being cooled to 4°C. 5ul of the RT Master Mix was added to the 
samples, with the reverse transcription being performed using the following 3 incubations:  
1. Samples incubated at 25°C for 3 minutes 
2. Samples incubated at 45°C for 10 minutes 
3. Samples incubated at 85°C for 5 minutes – to inactivate the RT Enzyme  




Key differences in gene expression and signalling pathways were analysed by qPCR. 
Quantitative PCR was performed on a Bio-rad CFX Maestro machine. qPCR was performed 






For each primer set used, an optimisation experiment was performed where a gradient of 
different anneal temperatures was used. The optimal anneal temperature was 
subsequently used to assess comparative gene expression levels. The qPCR reactions were 
performed using a semi-skirted 96 well plate, where 9ul of Master Mix was added in 
duplicates using the EDPA Multichannel Pipette for consistent accuracy inside a PCR 
preparation hood to prevent contamination. 1ul of cDNA was added to the corresponding 
duplicate wells before being covered by StarSeal Advanced Polyolefin Film to prevent 
sample evaporation. The plate was transferred to the Bio-Rad CFX Maestro machine and 
ran at the appropriate settings, including SYBR, melt curves and the correct temperature 




All analyses were performed on an n=3 where each n was obtained from a different batch 
of ECs from a different donor or donor pool. qPCR data underwent statistical analysis using 
a two-way analysis of variation test (2way ANOVA), with a Tukey post-hoc test using the 
GraphPad Prism 8 software. A P value < 0.05 was considered statistically significant. Graphs 






• SYBR Green • 5ul 
• DNase and RNase Free H2O • 3.6ul 
• 10µM Primer (forward and reverse) • 0.4ul 
• cDNA • 1uL 
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3.1 Primer optimisation  
 
To analyse gene expression under the flow conditions we used qPCR. To ensure optimal 
annealing temperatures were used for the genes, gradient qPCRs were performed on a 
CFX Bio-rad Maestro for all of the primer sets used in this study.  
Table 9: Primer Details.  Primers used in QPCR alongside their crucial data including; Gene name, primer 
sequence, CT Value, temperatures and ideal temperature range for primer usage. Red writing depicts 





range 58°C 60.8° 63.5° 66.9° 69.7° 71.2° 72° 
SRNX1 
756F   
GCCAAGGTGCAGAGCCTCGT 
32.6 31.68 30.53 33.16 N/A N/A N/A 
58-
63.5 757R   
GCGGGGATGGTCTCTCGCTG 
IκBα 
740F   
CGCCCAAGCACCCGGATACA 
30.11 29.98 30.03 30.30 33.60 39.50 N/A 
58-
66.9 741R   
AACGTCAGACGCTGGCCTCC 
VCAM1 
409F   
GCCCGGCTGGCTTTGGAGGC 
28.77 28.74 28.79 28.74 29.02 31.30 32.93 
58-
69.7 410R   
TGGTGACTCGCAGCCCGTAGTGC 
THMB 
232F   
CAACACACAGGGTGGCTTCG 
32.70 34.13 33.40 37.04 N/A N/A N/A 
58-
63.5 233R   
GGCTGGACAGGCAGTCTGGT 
CCL2 
704F    
ATTCCCCAAGGGCTCGCTCAG 
28.43 28.38 28.25 28.37 30.55 35.61 N/A 
58-
66.9 705R   
ACTTCTGCTTGGGGTCAGCACA 
KLF4 
369F   TGGACCCCCTCTCAGCAATG 
30.65 30.12 29.35 31.05 N/A N/A N/A 
58-
66.9 
370R   
CTCTTGGTAATGGAGCGGCG 
GCLM 
754F   
GTCCTTGGAGTTGCACAGCTGGA 
25.79 26.11 25.92 26.42 28.36 33.91 38.12 
58-
66.9 755R   
GGCATCACACAGCAGGAGGC 
GAPDH 
 181F           
AGTCCATGCCATCACTGCCACC 
23.14 23.17 23.31 25.19 35.98 N/A N/A 
58-
66.9 182R          
CAGGAAATGAGCTTGACAAAGTGG 
NOV 
716F   
TGGTGCGGCCCTGTGAACAA 
30.45 30.78 30.38 29.85 30.30 30.26 30.80 58-72 
717R   
AGCGGCCATCACTGCAGACC 
KLF2 
218F   
GTGAGAAGCCCTACCACTGCAACT 
28.51 28.45 28.18 29.91 N/A N/A N/A 
58-
66.9 219R    
CCGGTTCTCTGGGTCCAATAAATA 
eNOS 
204F   GCCGGAACAGCACAAGAGT 
31.58 30.88 30.30 34.58 N/A N/A N/A 
58-
63.5 
205R   GAGGATGCCAAGGCCGC 
768R   
CCGTGGCCACTGCAGGATGTA 




The melt curves of each of the primer sets were also analysed to ensure each primer set 
worked efficiently. For each primer set, an optimal annealing temperature was identified, 
allowing quantification of each gene product in the prepared cDNAs. Melt curves of each 
primer set were also recorded, demonstrating a dominant single peak for all primer sets, 
demonstrating only one desired amplicon was present. THMB and eNOS (Figure 9 and 15) 
demonstrate minor smaller peaks at all temperatures tested suggesting the presence of 
another size of amplicon. As each primer set spanned an intron, it is possible that this is a 
splice variant of the target gene, or may have been a contaminating amplicon for another 
gene. In both cases the area under the curve was considerably smaller than the large 
peak, suggesting a minimal effect on the total quantification of the amplicon.  
 
Figure 6: Melt curve for SRXN1 primer.      Figure 7: Melt curve for IκBα primer.   Figure 8: Melt curve for VCAM-1 primer. 
 
OSGIN1 
746F   
GGGAGCCTGGCACTCCATCG 
28.04 27.87 27.47 27.52 28.17 31.17 32.60 
58-
69.7 747R   
CCCGGCTGTTGCGAAGACCT 
CX3CL1 
718F   CTGTCGTGGCTGCTCCGCTT 
24.02 23.69 23.41 23.36 23.23 23.63 24.17 58-72 719R   
TCGGGTCGGCACAGAACAGC 
PI16 
611F   
ATGTGCGGCCACTACACGCA 
28.27 28.06 27.22 27.03 28.48 32.35 35.75 
58-
69.7  
612R   CCTTCACGTTCCCCGGAGGC 
RPLP0 
998F   
GCAGCAGATCCGCATGTCCC 
20.37 20.35 20.19 20.51 22.07 25.33 29.30 
58-
69.7 999R   
TCCCCCGGATATGAGGCAGCA 
PI16 
611F    
ATGTGCGGCCACTACACGCA 
30.79 29.35 27.49 26.40 26.49 27.46 28.45 
63.5-
72 626R   
TCAGTCGCCCGGAAGGATGG 
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Figure 9: Melt curve for THMB primer.        Figure 10: Melt curve for CCL2 primer.         Figure 11: Melt curve for E-selectin 
primer. 
Figure 12: Melt curve for KLF4 primer.        Figure 13: Melt curve for GCLM primer.         Figure 14: Melt curve for GAPDH.                                      
 
 
Figure 15: Melt curve for eNOS primer.      Figure 16: Melt curve for NOV primer.        Figure 17: Melt curve for KFL2 
primer. 
 











Figure 21: Melt curve for CX3CL1 primer.           Figure 22: Melt curve for OSGIN1 primer. 




3.2 Cell morphology 
 
Each individual batch of cells, cultured and grown from a 1ml vial, were imaged using the 
laboratory microscope at a 10X magnification, whilst seeded onto their glass slides prior to 
being dissembled from the parallel flow plates. Cell morphology was assessed to determine 
whether cells aligned to their allocated flow conditions. Each cell batch’s shape, size and 
structure were analysed and example morphologies are demonstrated in figure 23, figure 
24 and figure 25. 
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Figure 23: Cells cultured under static culture conditions. Cells under static culture appear to 
demonstrate a mostly elongated morphology. Cells under static culture are similar to those under 
oscillatory shear as figures 23 and 24 both show a lack of uniform along with a random 
orientation. ECFC batch 10 (B10) were of a lesser confluency than B11 and B8 under static culture. 










Figure 24: Cells under oscillatory culture conditions. Cells here show a polygonal morphology 
and are non-aligned, exhibiting a ‘lack of organisation’, this is a typical morphology demonstrated 
in cells exposed to disturbed shear. ECFC B10 are a lot less confluent than B11 and B8. HCAEC B7 
under oscillatory culture image missing due to loss of imagery on laboratory microscope.   
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Figure 25: Cells under laminar culture conditions. Cells show a longitudinal morphology, with 
a clear uniformed orientation. This demonstrates that the cells have aligned to the definite 
direction of  laminar flow, as expected, with ECFC B10 showing a slightly less confluent 
monolayer.  HCAEC B7 and HUVEC B2 under laminar culture images missing due to loss of imagery 
on laboratory microscope.  
 
Conclusion  
HCAECs, HUVECs and ECFCs all aligned to their allocated flow conditions accordingly, 
correlating to the biomechanosensitivty of vascular endothelial cells. Although HUVECs are 
of a naturally smaller nature, morphological and alignment variation can be disregarded, 
as they follow the same morphological and alingment patterns as HCAECs and ECFCs. Batch 
to batch variation in ECFCs is demonstrated in B10, with a visibly lesser confluency under 
LSS, OSS and static culture, compared to ECFC B8, B11, HCAEC batches and HUVECs, 
whereas minimal variation can be seen between HUVECs and HCAECs. Under all conditions, 
ECFCs demonstrate a more variable nature, under laminar culture ECFC batches are 
generally of lesser quantity and under oscillatory culture, ECFC B8 exhibit a disturbed flow 
organisatoin although, their mophology appears more elongated when compared to 
HUVEC and HCAEC batches.  
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3.3 KLF Regulated Genes 
The first identification of a KLF family member was made in 1993 where it was discovered 
in erythroid cells (Subramaniam M et al., 2010) with 18 known KLFs to date. Although all 
are regulators of gene expression and regulators of vascular homeostasis, they do not all 
share the same biological functions and are distributed amongst different tissues 
(Subramaniam M et al., 2010). KLF2 and KLF4 are members of the KLF family that express 
cytoprotective effects against vascular diseases and switching on approximately 1000 
genes, KLF2 is a flow-regulated integrator expressed in atheroprone regions of the human 
coronary arteries and induces anti-inflammatory (eNOS) and anti-thrombogenic (THMB) 
properties, along with NOV and PI16, whilst simultaneously inhibiting opposing factors ( 
VCAM1) (Parmar et al., 2005). KLF4 acts in concert with KLF2 to promote the athero-
protective phenotype in endothelial cells (Parmar et al., 2005). We therefore assessed the 
expression and regulation of KLF2 and KLF4 and a number of key KLF2/4 regulated genes in 




No significant upregulation of KLF2 by laminar flow was observed in ECFCs and HUVECs, 
compared to oscillatory shear stress or static culture, whereas in HCAECs KLF2 expression 
was significantly upregulated by laminar shear stress with a 13-fold change in LSS against 
oscillatory shear stress (P=0.028) and a 10-fold change against static culture (P=0.028) (Fig 
3.1, n=3). In relative terms, no significant differences were observed between the different 
cell types, indicating all three cell types express a similar level of KLF2 mRNA.  Therefore, 
HCAECs show a significant regulation of KLF2 by flow, however all HCAECs, HUVECs and 
ECFCs all express a similar level of KLF2 in identical culture conditions. 







































Figure 26: KLF2. A) The fold change of KLF2 mRNA for each cell line under static, oscillatory 
and laminar flow conditions for 72 hours, relative to the amount quantified in each cell 
type cultured under laminar flow. In HCAEC KLF2 expression was significantly upregulated 
by laminar flow, compared to culture in static or oscillatory conditions (P<0.05), whereas 
no significant difference was detected in HUVEC or ECFC.  B) Data displayed relative to 
HCAEC cultured under laminar flow, to allow comparison of the relative quantification of 
mRNA between cell types. No significant differences were found between any of the cell 
types under identical culture conditions. Data analysed using a 2-Way ANOVA, n=3, 




































Significant upregulation of KLF4 by laminar flow was observed in HCAEC, HUVEC and ECFC, 
compared to oscillatory and static culture. In HCAEC, KLF4 expression was significantly 
upregulated by laminar shear with a 28-fold change in LSS against oscillatory shear and a 
27-fold change against static culture. In HUVECS, KLF4 expression was significantly 
upregulated by laminar shear with an 11-fold change in LSS against oscillatory shear and a 
13-fold change against static culture. The fold induction of KLF4 by laminar flow was not 
significantly different between the 3 cell types. Relative to HCAECs, both HUVECs and ECFCs 
expressed similar levels of KLF4 in all 3 culture conditions, with HUVECs expressing less 
KLF4 compared to ECFCs in OSS. Therefore, HCAECs, HUVECs and ECFCs all show a 
significant upregulation of KLF4 by laminar flow; In addition, they all express similar levels 
of KLF4 in identical culture conditions compared to HCAECs.  
 
 
Figure 27: KLF4. A) The fold change of KLF4 mRNA for each cell line under static, oscillatory 
and laminar flow conditions for 72 hours, relative to the amount quantified in each cell 
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cell types KLF4 expression was significantly regulated by laminar flow, compared to 
culture in static or oscillatory conditions (P<0.05). C) Data displayed relative to HCAEC 
cultured under laminar flow, to allow comparison of the relative quantification of mRNA 
between cell types (D, displayed with Log10 Scale Y axis). HUVECs expressed significantly 
less KLF4 compared to ECFCs under identical oscillatory shear stress conditions. Data 




Significant upregulation of NOV by laminar flow was observed in HUVECs and HCAECs, 
compared to oscillatory and static culture. The changes in NOV expression in ECFCs with 
laminar flow did not achieve significance. In HCAECs, NOV expression was significantly 
upregulated by laminar flow shear with a 132-fold change in LSS against oscillatory shear 
and a 123-fold change under static culture. HUVECs expressed a 39-fold in oscillatory shear 
against LSS and a 21-fold change under static culture. ECFCs expressed significantly more 
NOV when cultured under OSS, compared to HUVECs (P=0.0150) and HCAECs (P=0.0237). 
Therefore, HUVEC and HCAEC show a significant upregulation to NOV by flow, while ECFCs 
did not significantly upregulate NOV with laminar flow. However, they all express similar 
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Figure 28: NOV. A) The fold change of NOV mRNA for each cell line under static, oscillatory 
and laminar flow conditions for 72 hours, relative to the amount quantified in each cell 
type cultured under laminar flow (B, same data presented on a Log10 Scale Y axis). In 
HUVEC and HCAEC, NOV expression was significantly regulated by laminar flow, 
compared to culture in static or oscillatory conditions (P<0.05). C) Data displayed relative 
to HCAEC cultured under laminar flow, to allow comparison of the relative quantification 
of mRNA between cell types (D, displayed with Log10 Scale Y axis). All 3 cell types 
expressed similar levels of NOV under static and Laminar flow conditions, however ECFCs 
expressed significantly more NOV under OSS. Data analysed using a 2-Way ANOVA, n=3, 




The expression of PI16 was significantly upregulated by laminar flow in HCAECs, HUVECs 
and ECFCs, compared to oscillatory and static culture. No detectable expression was 
demonstrated in HUVECs under static conditions or HCAECs under oscillatory flow. In 
relative terms, no significant differences were observed between the different cell types, 
indicating all three cell types express a similar level of PI16 mRNA. Therefore, HCAECs, 
HUVECs and ECFCs all show a significant upregulation to PI16 by flow, with similar level of 
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Figure 29: PI16. A) The fold change of PI16 mRNA for each cell line under static, oscillatory 
and laminar flow conditions for 72 hours, relative to the amount quantified in each cell type 
cultured under laminar flow (B, same data presented on a Log10 Scale Y Axis). In HCAECs, 
HUVECs and ECFCs, PI16 expression was significantly regulated by laminar flow, compared 
to culture in static or oscillatory conditions (P<0.05). C) Data displayed relative to HCAEC 
cultured under laminar flow, to allow comparison of the relative quantification of mRNA 
between cell types (D, displayed with Log10 Scale Y axis). No Significant differences were 
found between any of the cell types under identical flow conditions. Data analysed using a 
2-Way ANOVA, n=3, *p<0.05, **P<0.01, *** p<0.001. 
 
 3.3.6 eNOS 
 
Significant upregulation of eNOS by laminar flow was observed in HCAECs, However the 
changes in expression in HUVECs and ECFCs did not reach significance. In HCAECs, eNOS 
expression was significantly upregulated by laminar shear with a 14-fold change in LSS 
against oscillatory conditions and a 9-fold change under static culture. In relative terms, no 
significant differences were observed between the different cell types, indicating they all 
express similar level if eNOS mRNA. Therefore, HCAECs show a significant upregulation to 
eNOS by flow; however, they all express similar levels of eNOS mRNA in identical culture 









































































Figure 30: eNOS. A) The fold change of eNOS mRNA for each cell line under static, 
oscillatory and laminar flow conditions for 72 hours, relative to the amount quantified in 
each cell type cultured under laminar flow. In HCAEC, eNOS expression was significantly 
upregulated by laminar flow, compared to culture in static or oscillatory conditions 
(P<0.05).  B) Data displayed relative to HCAEC cultured under laminar flow, to allow 
comparison of the relative quantification of mRNA between cell types. No significant 
differences were found between any of the cell types under identical flow condition. Data 




Significant upregulation of THMB by laminar flow was observed in HCAECs and HUVECs 
between OSS and LSS. In ECFCs, no regulation by laminar flow was observed. In HUVECs 
and HCAECs, THMB expression was significantly upregulated by laminar shear (19-fold  and 
10-fold). THMB showed high levels of expression in static culture of HUVECs and HCAECs, 
highlighting the difference between the gene expression profiles of ECs cultured under 
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between the different cell types under identical culture conditions.  Therefore, HCAECs and 
HUVECs show a significant regulation of THMB by flow, while ECFCs did not, however no 
significant differences in expression levels of THMB were observed under identical culture 











Figure 31: THMB. A) The fold change of THMB mRNA for each cell line under static, 
oscillatory and laminar flow conditions for 72 hours, relative to the amount quantified in 
each cell type cultured under laminar flow (B, same data presented with Log10 Scale Y 
axis). In HUVEC and HCAEC, THMB expression was significantly regulated by laminar flow, 
compared to culture in oscillatory conditions (P<0.05). C) Data displayed relative to 
HCAEC cultured under laminar flow, to allow comparison of the relative quantification of 
mRNA between cell types (D, displayed with Log10 Scale Y axis). No Significant difference 
were found between any of the cell types under identical culture conditions. Data 















































































































42 | Page 
 
3.4 NRF2 Regulated Genes 
Nrf2 regulates a number of genes which serve to protect against antioxidant stress include 
HMOX1, NAPDH and oxidoreductase-1 (NQO1), Nrf2 activity is enhanced by KLF2 and Nrf2 
provides an element of the athero-protective phenotype induced by laminar shear stress 
(Satta et al., 2017, Nayak et al., 2011). Therefore, we assayed a number of Nrf2-regulated 
genes in HCAECs, HUVECs and ECFCs cultured under identical conditions to identify if shear 




Significant upregulation of HMOX1 by laminar flow was observed in HCAEC, but not HUVECs 
or ECFCs. In HCAECs, HMOX1 expression was significantly upregulated by laminar shear 
with a 2-fold change in LSS against oscillatory conditions and a 3-fold change under static 
culture. In relative terms, ECFCs expressed significantly more HMOX1 under oscillatory 
conditions compared to HUVECs (P=0.0491). Therefore, HCAEC show a significant 
upregulation of HMOX1 by flow; however, the level of expression was not significantly 






















































Figure 32: HMOX1. A) The fold change of HMOX1 mRNA expression for each cell line under 
static, oscillatory and laminar flow conditions for 72 hours, relative to the amount 
quantified in each cell type cultured under laminar flow. In HCAEC, HMOX1 expression 
was significantly regulated by laminar flow, compared to culture in static or oscillatory 
conditions (P<0.05). B) Data displayed relative to HCAEC cultured under laminar flow, to 
allow comparison of the relative quantification of mRNA between cell types. Significant 
differences were found between ECFCs and HUVECs under identical oscillatory conditions. 




A significant upregulation of OSGIN1 by laminar flow was observed in HCAECs, HUVECs and 
ECFCs. In HCAECs, OSGIN1 expression was significantly regulated by laminar shear with a 
4-fold change in LSS against oscillatory conditions and a 7-fold change under static culture. 
In HUVECs, OSGIN1 expression had a 5-fold change in LSS against oscillatory conditions, 
with a 3-fold change under static culture. ECFCs had a 2-fold change in LSS against 
oscillatory whilst under static culture, they had a 3-fold change. In relative terms, no 
significant differences were found between any of the cell types, indicating they all express 
a similar level of OSGIN1 mRNA. Therefore, HCAECs show significant upregulation of OSGIN 
mRNA by flow, HUVECs are significantly upregulated in LSS against oscillatory shear and 
ECFCs in LSS against static culture.  However, all cell types express a similar level of OSGIN1 
















































Figure 33: OSGIN1. A) The fold change of OSGIN1 mRNA for each cell line under static, 
oscillatory and laminar flow conditions for 72 hours, relative to the amount quantified in 
each cell type cultured under laminar flow. In HCAECs, HUVECs and ECFCs, OSGIN1 
expression was significantly regulated by laminar flow, compared to culture in static or 
oscillatory conditions (P<0.05). B) Data displayed relative to HCAEC cultured under 
laminar flow, to allow comparison of the relative quantification of mRNA between cell 
types. No Significant difference were found between any of the cell types under identical 






A significant upregulation of SRXN1 by laminar flow was observed in HCAEC but not HUVECs 
or ECFCs. In HCAECs, SRXN1 expression was significantly regulated by laminar shear with 
an 18-fold change in LSS against oscillatory conditions and a 64-fold change under static 
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under static culture, where ECFCs expressed significantly more SRXN1 then HCAECs, 
P=0.0396. Therefore, HCAECs show a significant regulation of SRXN1 by flow; however, all 
cell types express a similar level of SRXN1 under laminar and oscillatory conditions, with 


















Figure 34: SRXN1. A) The fold change of SRXN1 mRNA for each cell line under static, 
oscillatory and laminar flow conditions for 72 hours, relative to the amount quantified in 
each cell type cultured under laminar flow (B, same data presented on a Log10 Scale Y 
axis). In HCAEC, SRXN1 expression was significantly regulated by laminar flow, compared 
to culture in static or oscillatory conditions (P<0.05). C) Data displayed relative to HCAEC 
cultured under laminar flow, to allow comparison of the relative quantification of mRNA 
between cell types (D, displayed with Log10 Scale Y axis). Significant differences were 
found between ECFC and HCAEC under static shear conditions. Data analysed using a 2-




A significant upregulation of GCLM by laminar flow was observed in HCAEC but not HUVECs 
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4-fold change in LSS against static culture. In relative terms, no significant differences were 
found between any of the cell types, indicating they all express a similar level of GCLM 
mRNA. Therefore, HCAECs show a significant regulation of GCLM in LSS against static 












Figure 35: GCLM. A) The fold change of GCLM mRNA for each cell line under static, 
oscillatory and laminar flow conditions for 72 hours, relative to the amount quantified in 
each cell type cultured under laminar flow. In HCAEC, GCLM expression was significantly 
regulated by laminar flow, compared to culture in static or oscillatory conditions (P<0.05). 
B) Data displayed relative to HCAEC cultured under laminar flow, to allow comparison of 
the relative quantification of mRNA between cell types (C, displayed with Log10 Scale Y 
axis). No Significant difference were found between any of the cell types under identical 
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3.5 NFκB Regulated Genes 
Responsible for the induction of proinflammatory genes and leukocyte recruitment, 
promoting atherosclerosis, NFκB is a tightly regulated that regulates the expression of 
genes such as; VCAM1 and ICAM1 (Warboys et al., 2011). Therefore, we assayed the 
expression of NFκB-regulated genes in HCAECs, HUVECs and ECFCs under identical culture 




Significant upregulation of CX3CL1 by laminar flow was not observed in HCAEC, HUVEC or 
ECFC. In relative terms, no significant difference was found between the cell types, 
indicating they all express similar levels of CX3CL1. Therefore, all cell types are 
unresponsive to CX3CL1 under flow, with none of them showing a significant upregulation 
and no significant differences were found between the cell types under each flow 
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Figure 36: CX3CL1. A) The fold change of CX3CL1 mRNA for each cell line under static, 
oscillatory and laminar flow conditions for 72 hours, relative to the amount quantified in 
each cell type cultured under laminar flow. No significant regulation of CX3CL1 was 
observed in any of the cell types, compared to culture in static or oscillatory conditions 
(P<0.05). B) Data displayed relative to HCAEC cultured under laminar flow, to allow 
comparison of the relative quantification of mRNA between cell types (C, Displayed with 
Log10 Scale Y axis). No Significant differences were found between any of the cell types 
under identical flow condition. Data analysed using a 2-Way ANOVA, n=3, *p<0.05, 




Significant upregulation of VCAM1 by flow was observed in HCAECs. In HCAECs, VCAM1 
expression was significantly regulated by laminar shear with a 5-fold change in LSS against 
static culture. In relative terms, no significant differences were found between the cell 
types under the identical flow conditions. Therefore, HCAEC show a significant regulation 
of VCAM1 in LSS under static culture; however, HCAECs, HUVECs and ECFCs all express a 

















































Figure 37: VCAM1.  A) The fold change of VCAM1 mRNA for each cell line under static, 
oscillatory and laminar flow conditions for 72 hours, relative to the amount quantified in 
each cell type cultured under laminar flow. In HCAEC, VCAM1 expression was significantly 
regulated by laminar flow, compared to culture in static or oscillatory conditions (P<0.05). 
B) Data displayed relative to HCAEC cultured under laminar flow, to allow comparison of 
the relative quantification of mRNA between cell types. No significant differences were 
found between any of the cell types under identical flow conditions. Data analysed using 





Significant downregulation of CCL2 by laminar flow was observed in HCAECs, with a 4-fold 
change, but not in HUVEC or ECFCs. In HCAECs, CCL2 expression was reduced 4-fold in 
laminar shear compared to oscillatory shear. Therefore, HCAECs show a significant 
regulation of CCL2 by flow; however, all cell types express a similar level of CCL2 under the 































































































Figure 38: CCL2. A) The fold change of CCL2 mRNA for each cell line under static, 
oscillatory and laminar flow conditions for 72 hours, relative to the amount quantified in 
each cell type cultured under laminar flow (B, same data presented on a Log10 Scale 
graph). In HCAEC, CCL2 expression was significantly regulated by laminar flow, compared 
to culture in static or oscillatory conditions (P<0.05). C) Data displayed relative to HCAEC 
cultured under laminar flow, to allow comparison of the relative quantification of mRNA 
between cell types (D, displayed with Log10 Scale Y axis). No significant differences were 
found between any of the cell types under identical culture conditions. Data analysed 





Through the utilization of modern laboratory techniques and technologies, this project 
aimed to determine whether HUVECs and ECFCs would be suitable for cardiovascular 
research, as an alternative to the more expensive HCAECs. Using identical media and 
conditions, confluent monolayers of HCAECs, HUVECs and ECFCs were cultured for a 72-
hour period under static, oscillatory or laminar flow conditions. Each replicate was seeded 
from a single flask onto gelatin-coated slides and then cultured in parallel under the 
different conditions, to ensure that the only difference was the shear environment. Images 
of the cell types were taken along with collection of protein and RNA samples to carry out 
molecular analysis techniques.  The gene expression from each cell line was then examined 
by qPCR using identical materials and methods, and performing the qPCRs for each gene 
within the same reaction, to ensure that there was uniformity in assessing the expression 
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4.1 Utility of cell types in cardiovascular research  
HCAECs might be considered the gold standard for research into cardiovascular disease 
because they are obtained from the anatomical site associated with the most significant 
impact of atherosclerosis. HCAECs originate from a different embryonic origin compared to 
other arterial cells, potentially making their use in studies into the processes that regulate 
atherosclerosis even more important. The major drawback from using HCAECs is the price, 
making them unaffordable in some laboratories. It also reduces the ability to study HCAECs 
from multiple donors with particular risk factors (e.g. smokers or diabetics, or male v 
female donors) to examine the genetic or epigenetic effects of these risk factors on disease 
processes. HCAEC have been reported to have a greater susceptibility to inflammation 
compared to HUVECs as indicated by a research study performed by Lakota et al., (Lakota 
et al., 2009). Whilst little to no research has been conducted into ECFC appropriacy in 
disease modelling, one beneficial aspect of the cell line is their accessibility. ECFC are 
derived from the buffy coat layer in the blood, where they can be cultured and grown to 
desirable quantity as well as being derived from the of blood multiple patient groups, 
including those who are affected by diseases characterized by inflammation (Edwards et 
al., 2018). For example, ECFCs from patients with type 2 diabetes maintain a diseased 
phenotype have reduced angiogenic capacity and mitochondrial dysfunction and changes 
in energy metabolism compared to ECFCs from non-diabetic donors (Edwards et al., 2018).  
In atherosclerosis, it has been suggested that a high ECFC count may exert an 
atheroprotective effect in response to vascular damage, where they migrate to the site of 
injury and begin repair through the actions of endothelial cell replenishment and 
atherogenesis (Edwards et al., 2018).  
 
4.2 Molecular regulation of atherosclerosis 
In all aspects of atherosclerosis, blood flow is crucial for either pathogenesis of the disease 
or protection. Shear stress can be defined as a ‘frictional force per unit area from flowing 
blood’ acting upon the endothelium to control the morphology, structure and biochemical 
changes in EC lining the artery (Hahn and Schwartz, 2009). Atherosclerosis develops at 
bifurcation sites in the arteries, where oscillatory blood flow can mediate the foundations 
for disease development and progression (Hahn and Schwartz, 2009). Lesions found in 
these areas contain lipids, leukocytes and migrated smooth muscle cells which can 
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collectively lead to cholesterol crystal and calcification-containing necrotic cores; offering 
much greater and severe consequences (Hahn and Schwartz, 2009).  
Laminar shear stress induces pathways mediated by transcription factors KLF2/4 and Nrf2, 
driving an atheroprotective response through the upregulation of anti-inflammatory and 
antioxidant genes (Fledderus et al., 2008; Satta et al., 2017). Although Nrf2 is recognised as 
an atheroprotective pathway through the regulation of the oxidant/ antioxidant system, it 
may also contribute to the pathogenesis of endothelial erosion, if very high-level activation 
of Nrf2 is sustained (Satta et al., 2019).  NFκB is a pathway induced by disturbed shear 
stress, driving a proinflammatory response through genes such as ICAM1, VCAM1 and 
cytokines such as TNF-a, with coordinated regulation of the MAPK pathway (Warboys et 
al., 2011). The drive seen in the inflammatory response correlates with the development 
of atherogenesis, favouring detrimental cellular effects including poor alignment to flow 
(Hahn and Schwartz, 2009).  
 
4.2.1 Krupple-Like Factor Gene Regulation 
The data presented within this study shows that laminar flow significantly upregulates both 
KLF2 and KLF4 in HCAEC, resulting in an increase of expression of all of the genes known to 
be regulated by KLF2/4 in endothelial cells. This universal response was not observed for 
HUVECs and ECFCs, which demonstrated variable regulation of KLF2 +4 and their regulated 
genes by laminar flow. HUVECs and ECFCs did not significantly increase the expression of 
KLF2 under laminar flow conditions, however there was a significant and similar 
upregulation of KLF4 in all 3 cell types by laminar flow. Similarly, the KLF-regulated genes 
appeared to be regulated by flow on a continuum between the KLF4 and KLF2 pattern of 
regulation. PI16 demonstrated a very large upregulation by laminar flow in all cell types, 
similar to KLF4. NOV demonstrated a large upregulation in HCAECs and HUVECs with 
laminar flow, as well as THMB. The expression of eNOS almost exactly mirrored that of 
KLF2. This might suggest the relative importance that either KLF2 or KLF4 plays in the 
regulation of each genes across the different cell types.  
 
An observation made solely in THMB provides evidence that, contrary to popular belief, 
static culture is not the same as oscillatory culture and should not be used as an alternative 
model for oscillatory shear. In HCAECs and HUVECs, the expression of THMB was 
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significantly upregulated under static shear stress against oscillatory shear stress, 
underlining the differential expression pattern in static and OSS culture.  
 
4.2.2 Nuclear Erythroid like Factor 2 Regulation 
We demonstrated that there were also differences between HCAECs, HUVECs and ECFCs in 
the shear-regulation of known Nrf2-regulated genes.  HCAEC demonstrated a significant 
upregulation of HMOX1, OSGIN1, SRXN1 and GCLM, the relevant Nrf2-regulated genes, by 
laminar sheer stress. HUVECs and ECFCs both only demonstrated a significant upregulation 
of OSGIN1 with laminar shear stress, from the Nrf2-regulated genes tested.  HUVEC and 
ECFC present with a large variation across Nrf2 regulated genes as well as NFκB, suggesting 
a large donor effect on the regulation of these genes. Increasing the number of donors 
tested might help determine if laminar shear stress significantly regulates these genes in 
HUVECs and ECFCs.  
 
4.2.3 Nuclear Factor Kappa B Regulation 
Data presented from our research on the NFκB regulated genes shows, HCAECs, HUVECs 
and ECFCs all demonstrate differences. In HCAECs, CCL2 demonstrated a downregulation 
by laminar flow, whilst in HUVECS, no significant regulation of the NFκB regulated genes by 
flow was observed (CX3CL1, VCAM1 and CCL2). TNF- α is a crucial proinflammatory cytokine 
which drives inflammation pathways including NFκB and can rapidly induce the 
transcription of genes involved in inflammation and cell proliferation and differentiation 
(Gupta et al., 2005). Introducing TNF-α in a separate study may be useful in determining 
further response of NFκB genes, due to the influence of TNF-α , in HUVECs and ECFCs. Data 
sets from both studies can then be used in a side by side comparison to note the effects of 
introduction of TNF-α.  
 
4.3 Cell morphology 
The mechanosensitive abilities of vascular endothelial cells are demonstrated through the 
correct morphological qualities and flow alignment in HCAECs, HUVECs and ECFCs. ECFCs 
appear less responsive to tissue culture, as their confluency varies from batch to batch and 
is visibly less between cell types. These variations may be due to donor differences or the 
general nature of ECFCs, the variation in ECFCs, compared to HUVECs and HCAECs, across 
atherosclerotic relevant genes that we tested are possibly linked to the variation 
demonstrated in the cell morphology.  




Our data concludes that HCAECs are the most responsive cell type in the KLF, Nrf2 and NFκB 
pathways, with significant upregulation of most genes in response to flow, with the only 
exception being CX3CL1, and therefore remain the most appropriate cell type to model 
atherosclerosis. HUVECs mostly demonstrate a significant upregulation of the genes 
collectively and therefore would be an ideal cell model, however further work with a larger 
N number should be done to confirm this. ECFCs can now be addressed as the most 
unresponsive cell type, with few significant upregulations to genes by flow and can be 
deemed inappropriate cell models for atherosclerosis research.  
 
5.0 Future Work 
There are many ways in which this set of experiments could be enhanced. Primarily, 
increasing the number of batches of cells used would allow the detection of smaller 
differences in gene expression to be observed. Due to time and money constraints we were 
limited to an n=3 for each cell type, with each replicate being derived from a different 
donor. This had a large effect on the ability to detect small changes in shear-regulated gene 
expression. The large variation seen between donors was a major limiting factor in this 
study. Similarly, additional types of analyses could be employed, including next generation 
sequencing to perform an unbiased assessment of gene expression could have been 
performed, rather than the limited assessment of key shear-regulated genes performed in 
this study. Widening the measurement of gene expression to include the quantification of 
changes in protein expression would account for potential regulation by microRNAs, which 
might regulate translation in a cell type-dependent manner.   
An aspect not covered in this research project is the potential use of induced pluripotent 
stem cells (IPS). IPS are reprogrammed into a state of embryonic-like pluripotency, and 
then differentiated into a variety of human cells (Stemcell.ucla.edu, 2019). Following the 
generation of IPS cells, a new opportunity arose in the field of cardiovascular research and 
recent advances into stem cells has offered great potential for the use of IPS in cardiac 
research and regenerative medicine (Martins, Vunjak-novakovic and Reis, 2014). The 
nature of IPS cells residence, skin and blood from adult somatic cells, means ethical issues 
are not of any concern (Martins, Vunjak-novakovic and Reis, 2014). Additionally, IPS cells 
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offer no implications with transplantation rejection, since the cells themselves are derived 
from the patient’s own blood or skin, offering more beneficial advantages in research and 
regenerative medicine (Martins, Vunjak-novakovic and Reis, 2014). IPS can be 
differentiated into endothelial cells, and offers the potential to examine EC function from 
patients with known genetic susceptibility to cardiovascular disease. Functional 
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7.0 Appendix  




Participant Information Sheet 
Version 2; 14th February, 2017. 
 




You are being invited to take part in a research study. Before you decide, it is important 
for you to understand why the research is being done and what it will involve. Please take 
time to read the following information carefully and discuss it with friends and relatives if 
you wish. Ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
Damage to the lining of blood vessels (endothelial dysfunction) underlies many diseases 
associated with inflammation and a high cardiovascular disease risk eg Type II Diabetes, 
Systemic Lupus Erythematosus (an auto-immune disease) and atherosclerosis (clogging or 
hardening of the blood vessels). 
 
Cells and microvesicles (small particles released from blood cells) circulating in the blood 
are thought to play an important role in the health and maintenance of this delicate lining of 
the blood vessels, which become damaged during disease. The molecular and cellular 
mechanisms by which these cells and microvesicles influence blood vessel repair 
processes in disease are poorly understood. 
 
The purpose of this project is to investigate the interaction between these damaged cells, 
microvesicles, inflammation and repair using a disease model that we can study in the 
laboratory. 
 
Cells and blood plasma microvesicles can be harvested from the blood. We can grow the 
cells in the laboratory and subject them to various treatments to recapitulate disease 
conditions. We can investigate the function of these cells and microvesicles and examine 
the molecules and proteins that are altered in disease-like conditions compared to untreated 
cells.  
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This study is an early step in the complicated process of identifying markers in human 
patients who have endothelial dysfunction in diseases including type II diabetes and 
hardening of the arteries, which will be done in a complimentary project. This model will 
allow us to estimate the future development of disease and allow us to develop new 
therapeutic targets and biomarkers of disease. 
 
We would like to invite you to help us identify these proteins and molecules, which 
are involved in this disease process by allowing us to take a sample of your blood, 
so that we may in the future prevent some of the vascular disease that amounts to 
one of the leading causes of death in the western world.  
 
What will I have to do if I take part? 
If you agree to take part you would be asked to donate a 60 ml sample of blood. This is a 
simple procedure carried out by a trained phlebotomist in our department and should take 
no more than 10 minutes. We will assign a number to your sample and your name will be 
kept confidential.  
 
What are the possible risks of taking part? 
You may experience a sharp scratch sensation for a second when the phlebotomist takes 
your blood via a small needle. The blood will be taken whist sitting in a comfortable, private 
and hygienic environment. Let the phlebotomist know if you have ever experienced fainting 
when giving blood previously. 
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Participant Information Sheet  (continued) “Investigating endothelial 




Do I have to take part? 
No, taking part is voluntary.  If you would prefer not to take part, you do not have to give a 
reason.  If you do decide to take part, we will ask you to sign a consent form and give you 
a copy of this information sheet and consent form to keep. If you decide to take part, you 
are still free to withdraw at any time.   
 
What will happen to the results of the research study? 
The results of the study will be published in scientific journals, presented as scientific 
conferences and at public engagement events. Your name will not be identified.  
 
 





If you wish to obtain advice about this research you may contact: 
 
Dr Fiona Wilkinson 
Telephone: 0161 247 3349 
Professor Yvonne Alexander  
Tel: 0161 2475428 
Healthcare Science 
Manchester Metropolitan University, 
Manchester. M15GD  
 
